Xenon Pharmaceuticals (XENE) announced the appointment of Darren Cline as Chief Commercial Officer and member of the Xenon senior executive team. In this role, Cline will lead commercial strategy and operations for the Company’s portfolio of product and development candidates, with initial focus on its lead Phase 3 candidate, azetukalner, and first potential launch in epilepsy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Positive Outlook for Xenon Pharmaceuticals Driven by Promising Drug Pipeline and Strategic Trial Developments
- Xenon Shareholders Approve Key Proposals at Annual Meeting
- Xenon Pharmaceuticals to Present at Global Healthcare Conference
- Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees
- Xenon Pharmaceuticals’ Earnings Call Highlights Progress and Optimism